A Phase 2 interventional study of Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections and Monthly placebo infusions + 3 times per week placebo injections in ALS (Amyotrophic Lateral Sclerosis), sponsored by The Methodist Hospital Research Institute. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by The Methodist Hospital Research Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 244th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2019, is one of 89 in phase 2, and was the 246th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 20 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
The Methodist Hospital Research Institute is the lead sponsor of 162 studies on the registry; 61 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 18 (64%) have results posted.
The Methodist Hospital Research Institute has 4 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same person whose Treg were removed, given back by IV (intravenously) and in combination with low-dose IL-2 in people with Amyotrophic Lateral Sclerosis (ALS).
Based on data collected in a previous study with a small group of patients, evidence was found to show that interfering with the immune system using Treg cells slowed ALS disease progression. It is known that Treg cell numbers and function are reduced in patients with ALS and in some patients with lower Treg cells, they have a more marked rapid progression of their ALS. For this study, there are two sites (in Houston, Texas and Boston, Massachusetts) in which Tregs will be taken from participants, increased or expanded outside the body, and then re-administered back to the participants from which the Tregs came.
This study has two parts and due to the pandemic two groups [Group 1 and Group 2]:
Groups:
GROUP 1 will go through the double-blind part of the study (receive either Tregs infusions and IL2 injections OR saline infusions and saline injections) for six months and open label part of the study (receive Treg injections and IL2 injections) for six months.
GROUP 2 will receive only the open label (Tregs infusions and IL2 injections) for six months.
This study is studying whether the enhancement of Treg numbers and function will slow disease progression.
In the first study of Tregs, we completed a single-center, open-label phase I study of Tregs from people with ALS. Tregs were increased outside the body and returned back to the individual Treg owners in multiple doses every 2 to 4 weeks. This early study provided evidence in a small group of patients that treatment with autologous Tregs may be effective in slowing ALS progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of any of the following clinical conditions that would interfere with the safe conduct of the study, as determined by the Investigator:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.
Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.
Other: Monthly placebo infusions + 3 times per week placebo injections
For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.
Biological: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
Also known as: Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is brand name for IL-2
For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
Also known as: inactive drug
For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
Also known as: Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is the brand name for IL-2
Change in Treg Suppressive Function in the Blood From Baseline to Week 24.
Change in Treg suppressive function on the proliferation of T-effector cells, as measured in percentage at baseline compared to week 24. Cohort 1-participants randomized to Tregs and IL-2 or matching placebos (no Tregs and saline. Cohort 2-participants from Cohort 1 who completed 6 Treg or placebo infusions and weekly IL-2 or placebo infusions plus 2 participants who went straight into Cohort 2 - Tregs and IL-2 (no placebo).
Time frame: Baseline and week 24.
Change in Treg Numbers in the Blood From Baseline to Week 24.
Change in Treg numbers in the blood at baseline compared to week 24; measured in % of total CD4+ cells.
Time frame: Baseline and week 24
Tolerability of Treg Infusions for 6 Months of Treatment
Defined as the percentage of participants who complete the 6-month RCT.
Time frame: Baseline to week 24.
Tolerability of Ascending Doses of Tregs for 6 Months of Treatment
Defined as the percentage of participants who complete the ascending doses of Tregs.
Time frame: Baseline to week 24.
Enrollment occurred from 08/14/2019 to 04/03/2020 at two academic ALS centers. Seven participants entered Period 1 (RCT): 4 placebo and 3 Treg/IL-2. Six completed the RCT and continued into Period 2 (OLE): 3 placebo and 3 Treg/IL-2; 1 placebo participant discontinued after a serious adverse event. Due to COVID-19-related impacts, 2 additional participants entered directly into the OLE, for 8 total OLE participants.
| Milestone | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Started | 3 | 4 | 0 |
| Continued to ole | 3 | 3 | 0 |
| Completed | 3 | 3 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Started | 0 | 0 | 8 |
| Completed | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 |
Change in Treg suppressive function on the proliferation of T-effector cells, as measured in percentage at baseline compared to week 24. Cohort 1-participants randomized to Tregs and IL-2 or matching placebos (no Tregs and saline. Cohort 2-participants from Cohort 1 who completed 6 Treg or placebo infusions and weekly IL-2 or placebo infusions plus 2 participants who went straight into Cohort 2 - Tregs and IL-2 (no placebo).
| percentage of Treg suppressive function | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Change in Treg Suppressive Function in the Blood From Baseline to Week 24. | 30.2 ± 15.8 | 26.3 ± 18.3 | 28.0 ± 15.9 |
Change in Treg numbers in the blood at baseline compared to week 24; measured in % of total CD4+ cells.
| percentage of total CD4+ cells | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Change in Treg Numbers in the Blood From Baseline to Week 24. | 3.17 ± 0.55 | 4.45 ± 2.38 | 3.90 ± 1.84 |
Defined as the percentage of participants who complete the 6-month RCT.
| Participants | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Tolerability of Treg Infusions for 6 Months of Treatment | 3 | 3 | 8 |
Defined as the percentage of participants who complete the ascending doses of Tregs.
| Participants | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Tolerability of Ascending Doses of Tregs for 6 Months of Treatment | 3 | 3 | 8 |
Collected over Adverse Events were collected from the time the consent form was executed throughout the study, up to 15 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous Infusion of Treg Cells + Interleukin-2 Injections | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Intravenous Infusion w/Placebo + Matching Placebo Injections | 0/4 (0%) | 1/4 (25%) | 0/4 (0%) |
| 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Intravenous Infusion w/Placebo + Matching Placebo Injections | 2nd 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| Anaphylaxis reaction to the 2nd double-blind infusionImmune system disorders | 0/3 | 1/4 | 0/8 |
| Event | Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Intravenous Infusion w/Placebo + Matching Placebo Injections | 2nd 6-months Open Label: Treg Infusions + IL-2 Injections |
|---|---|---|---|
| increased lacrimationEye disorders | 0/3 | 0/4 | 1/8 |
11 Participants signed consent for the study, 9 were eligible for treatment. Six (6) participants who completed Cohort 1 are included in Cohort 2. Two (2) participants only participated in Cohort 2 only. One participant in Cohort 1 had 2 infusions, the second one was interrupted and stopped early due to an infusion reaction.
| Age, Categorical(Participants) | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 4 | 1 | 8 |
| >=65 years | 0 | 0 | 1 | 1 |
| Age, Continuous(years) | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | Total |
|---|---|---|---|---|
| Median | 46.2 ± 5.6 | 52.5 ± 6.8 | 49.7 ± 11 | 49.8 ± 6.7 |
| Sex: Female, Male(Participants) | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | Total |
|---|---|---|---|---|
| Female | 1 | 0 | 1 | 2 |
| Male | 2 | 4 | 1 | 7 |
| Race (NIH/OMB)(Participants) | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 4 | 2 | 9 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 4 | 2 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(country) | Cohort 1: Intravenous Infusion of Treg Cells + Interleukin-2 Injections | Cohort 1: Intravenous Infusion w/Placebo + Matching Placebo Injections | Cohort 2: 2nd 6-months Open Label: Treg Infusions + IL-2 Injections | Total |
|---|---|---|---|---|
| United States | 3 | 4 | 2 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified data may be shared with requests directed to the research clinical investigators.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: At the end of the study via data management plan for duration of Treg studies.
Access criteria: Request to PI.
Ran from Aug 2019 to primary completion in Aug 2021, 24 months.
Results were first posted in Oct 2026, 5 years 1 month after primary completion.
Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's 24 months is below that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion May 2022 → Aug 2021 and completion Aug 2022 → Sep 2021.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
The Methodist Hospital Research Institute →